The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Stefano Cascinu

Clinica di Oncologia Medica

AO Ospedali Riuniti

Università Politecnica delle Marche

Via Conca



Name/email consistency: high



  • Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Via Conca, Italy. 2011
  • Clinica di Oncologia Medica, Universita' Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Italy. 2004 - 2009
  • Polytechnic University of Marche-Riuniti Hospital Umberto I-GM Lancisi-G Salesi of Ancona, 60020 Ancona, Italy. 2008
  • Department of Medical Oncology, Università Politecnica delle Marche, Ancona, Italy. 1999 - 2008
  • Universita' Politecnica delle Marche, Via Conca 60020 Ancona, Italy. 2007
  • Division of Medical Oncology, Azienda Ospedaliera Ospedale S. Salvatore, Pesaro, Italy. 1999 - 2002
  • Department of Medical Oncology, Azienda Ospedaliera-Universitaria di Parma, via Gramsci 14, 43100 Parma, Italy. 2002
  • Medical Oncology, Azienda Ospedaliera di Parma, Italy. 2000 - 2001


  1. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cascinu, S., Galizia, E., Labianca, R., Ferraù, F., Pucci, F., Silva, R.R., Luppi, G., Beretta, G.D., Berardi, R., Scartozzi, M. Cancer Chemother. Pharmacol. (2011) [Pubmed]
  2. Hepatocellular carcinoma: The beginning of a long journey. Cascinu, S. Dig. Liver. Dis (2009) [Pubmed]
  3. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Cascinu, S., Berardi, R., Labianca, R., Siena, S., Falcone, A., Aitini, E., Barni, S., Di Costanzo, F., Dapretto, E., Tonini, G., Pierantoni, C., Artale, S., Rota, S., Floriani, I., Scartozzi, M., Zaniboni, A. Lancet Oncol. (2008) [Pubmed]
  4. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Cascinu, S., Berardi, R., Salvagni, S., Beretta, G.D., Catalano, V., Pucci, F., Sobrero, A., Tagliaferri, P., Labianca, R., Scartozzi, M., Crocicchio, F., Mari, E., Ardizzoni, A. Br. J. Cancer (2008) [Pubmed]
  5. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Cascinu, S., Scartozzi, M., Carbonari, G., Pierantoni, C., Verdecchia, L., Mariani, C., Squadroni, M., Antognoli, S., Silva, R.R., Giampieri, R., Berardi, R. Am. J. Clin. Oncol. (2007) [Pubmed]
  6. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. Cascinu, S., Labianca, R., Barone, C., Santoro, A., Carnaghi, C., Cassano, A., Beretta, G.D., Catalano, V., Bertetto, O., Barni, S., Frontini, L., Aitini, E., Rota, S., Torri, V., Floriani, I., Pozzo, C., Rimassa, L., Mosconi, S., Giordani, P., Ardizzoia, A., Foa, P., Rabbi, C., Chiara, S., Gasparini, G., Nardi, M., Mansutti, M., Arnoldi, E., Piazza, E., Cortesi, E., Pucci, F., Silva, R.R., Sobrero, A., Ravaioli, A. J. Natl. Cancer Inst. (2007) [Pubmed]
  7. New target therapies in advanced pancreatic cancer. Cascinu, S., Verdecchia, L., Valeri, N., Berardi, R., Scartozzi, M. Ann. Oncol. (2006) [Pubmed]
  8. Gastric cancer treatment: a systematic review. Berardi, R., Scartozzi, M., Romagnoli, E., Antognoli, S., Cascinu, S. Oncol. Rep. (2004) [Pubmed]
  9. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu, S., Scartozzi, M., Labianca, R., Catalano, V., Silva, R.R., Barni, S., Zaniboni, A., D'Angelo, A., Salvagni, S., Martignoni, G., Beretta, G.D., Graziano, F., Berardi, R., Franciosi, V. Br. J. Cancer (2004) [Pubmed]
  10. Pain and its treatment in hospitalized patients with metastatic cancer. Cascinu, S., Giordani, P., Agostinelli, R., Gasparini, G., Barni, S., Beretta, G.D., Pulita, F., Iacorossi, L., Gattuso, D., Mare, M., Munaò, S., Labianca, R., Todeschini, R., Camisa, R., Cellerino, R., Catalano, G. Support. Care. Cancer (2003) [Pubmed]
  11. Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen. Cascinu, S., Baldelli, A.M., Catalano, V., Giordani, P., Beretta, G.D., Silva, R.R., Gasparini, G., Mari, D., Maisano, R., Salvagni, S., Barni, S., Labianca, R., Frontini, L., Curti, C., Catalano, G. Br. J. Cancer (2002) [Pubmed]
  12. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Cascinu, S., Graziano, F., Catalano, V., Staccioli, M.P., Rossi, M.C., Baldelli, A.M., Barni, S., Brenna, A., Secondino, S., Muretto, P., Catalano, G. Br. J. Cancer (2002) [Pubmed]
  13. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Cascinu, S., Graziano, F., Ferraù, F., Catalano, V., Massacesi, C., Santini, D., Silva, R.R., Barni, S., Zaniboni, A., Battelli, N., Siena, S., Giordani, P., Mari, D., Baldelli, A.M., Antognoli, S., Maisano, R., Priolo, D., Pessi, M.A., Tonini, G., Rota, S., Labianca, R. Ann. Oncol. (2002) [Pubmed]
  14. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A.M., Beretta, G.D., Ubiali, E., Catalano, G. J. Clin. Oncol. (2002) [Pubmed]
  15. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cascinu, S., Del Ferro, E., Ligi, M., Staccioli, M.P., Giordani, P., Catalano, V., Agostinelli, R., Muretto, P., Catalano, G. Cancer Invest. (2001) [Pubmed]
  16. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Cascinu, S., Graziano, F., Valentini, M., Catalano, V., Giordani, P., Staccioli, M.P., Rossi, C., Baldelli, A.M., Grianti, C., Muretto, P., Catalano, G. Ann. Oncol. (2001) [Pubmed]
  17. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Catalano, V., Baldelli, A.M., Giordani, P., Cascinu, S. Crit. Rev. Oncol. Hematol. (2001) [Pubmed]
  18. Survival and quality of life in gastrointestinal tumors: two different end points?. Cascinu, S., Labianca, R., Daniele, B., Beretta, G., Salvagni, S. Ann. Oncol. (2001) [Pubmed]
  19. Effects of calcium and vitamin supplementation on colon cell proliferation in colorectal cancer. Cascinu, S., Ligi, M., Del Ferro, E., Foglietti, G., Cioccolini, P., Staccioli, M.P., Carnevali, A., Luigi Rocchi, M.B., Alessandroni, P., Giordani, P., Catalano, V., Polizzi, V., Agostinelli, R., Muretto, P., Catalano, G. Cancer Invest. (2000) [Pubmed]
  20. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Cascinu, S., Staccioli, M.P., Gasparini, G., Giordani, P., Catalano, V., Ghiselli, R., Rossi, C., Baldelli, A.M., Graziano, F., Saba, V., Muretto, P., Catalano, G. Clin. Cancer Res. (2000) [Pubmed]
  21. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Cascinu, S., Catalano, V., Aschele, C., Barni, S., Debernardis, D., Gallo, L., Bandelloni, R., Staccioli, M.P., Baldelli, A.M., Brenna, A., Valenti, A., Muretto, P., Catalano, G. Ann. Oncol. (2000) [Pubmed]
  22. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu, S., Frontini, L., Labianca, R., Catalano, V., Barni, S., Graiff, C., Picone, G., Farinati, E., Zonato, S., Pessi, M.A., Curti, C., Catalano, G. Ann. Oncol. (2000) [Pubmed]
  23. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Cascinu, S., Graziano, F., Catalano, V., Staccioli, M.P., Barni, S., Giordani, P., Rossi, M.C., Baldelli, A.M., Muretto, P., Valenti, A., Catalano, G. Clin. Exp. Metastasis (2000) [Pubmed]
  24. Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Cascinu, S., Giordani, P., Catalano, V., Agostinelli, R., Catalano, G. Jpn. J. Clin. Oncol. (1999) [Pubmed]
  25. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu, S., Gasparini, G., Catalano, V., Silva, R.R., Pancera, G., Morabito, A., Giordani, P., Gattuso, D., Catalano, G. Ann. Oncol. (1999) [Pubmed]
WikiGenes - Universities